HUMANIGEN: Moving forward while others stumble | BUY | USD30
HUMANIGEN - BUY | USD30Moving forward while others stumble
New clinical site is actively enrolling hospitalized COVID patients
Expecting lenzilumab to excel, while competition stumble
Lenzilumab is ahead of anti-GM-CSF pack
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.